Candel Therapeutics (CADL) Cash from Operations (2020 - 2023)
Historic Cash from Operations for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$7.4 million.
- Candel Therapeutics' Cash from Operations fell 779.96% to -$7.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$34.2 million, marking a year-over-year decrease of 899.14%. This contributed to the annual value of -$27.0 million for FY2024, which is 2108.69% up from last year.
- As of Q4 2023, Candel Therapeutics' Cash from Operations stood at -$7.4 million, which was down 779.96% from -$8.8 million recorded in Q3 2023.
- Candel Therapeutics' 5-year Cash from Operations high stood at -$1.5 million for Q3 2020, and its period low was -$10.8 million during Q1 2023.
- Moreover, its 4-year median value for Cash from Operations was -$7.0 million (2021), whereas its average is -$6.6 million.
- Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 35807.31% in 2021, then surged by 613.81% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Cash from Operations stood at -$3.4 million in 2020, then tumbled by 53.34% to -$5.2 million in 2021, then crashed by 31.44% to -$6.9 million in 2022, then fell by 7.8% to -$7.4 million in 2023.
- Its Cash from Operations was -$7.4 million in Q4 2023, compared to -$8.8 million in Q3 2023 and -$7.2 million in Q2 2023.